🔍

JHS - JHS Sven.Lab.

📊 NSE: JHS 🏢 Personal Care - Indian 📅 Last Updated: 12/14/2025 8:37

📢 Recent Corporate Announcements

JHS Svendgaard Appoints M/s A.R. & Co. as Internal Auditor for 3-Year Tenure

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 05:53 PM

JHS Svendgaard Laboratories Limited has appointed M/s A.R. & Co., Chartered Accountants, as the company's Internal Auditor. The appointment was approved by the Board of Directors on February 10, 2026, for a period of three financial years spanning 2025-26 to 2027-28. The appointed firm brings over 44 years of experience, having been established in 1981 with a background in large government and diverse audits. This is a standard regulatory compliance move under SEBI LODR Regulations.

Appointment of M/s A.R. & Co. as Internal Auditor for 3 financial years
Tenure covers the period from FY 2025-26 to FY 2027-28
The auditing firm has over 44 years of experience since its establishment in 1981
Board approval for the appointment was finalized on February 10, 2026

💡 This is a routine administrative disclosure regarding corporate governance. No immediate action is required as it does not impact the company's financial fundamentals.

JHS Svendgaard Q3 FY26 Results: Standalone Revenue at ₹23.18 Cr, Reports Marginal Net Loss

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 10 Feb 2026, 05:50 PM

JHS Svendgaard reported a standalone revenue of ₹23.18 crore for Q3 FY26, a slight decline from ₹23.66 crore in the same quarter last year. The company posted a marginal standalone net loss of ₹3.08 lakhs compared to a profit of ₹63.67 lakhs YoY, though it showed sequential improvement from a loss of ₹115.28 lakhs in Q2 FY26. A significant development is the lapse of 18.01 lakh warrants due to non-conversion within prescribed timelines, while another 18.01 lakh warrants were converted into equity. The company still holds ₹9.38 crore in fixed deposits from its previous fundraise, pending utilization for its Jammu and Kashmir project and other corporate purposes.

Standalone Revenue from operations stood at ₹2,318.18 lakhs, down 2% YoY from ₹2,365.95 lakhs.
Reported a standalone net loss of ₹3.08 lakhs for Q3 FY26 against a profit of ₹63.67 lakhs in Q3 FY25.
Total expenses for the quarter were ₹2,377.29 lakhs, exceeding the total income of ₹2,373.71 lakhs.
18.01 lakh warrants lapsed due to non-conversion, while 18.01 lakh warrants were converted into equity shares at ₹27.75 per share.
Company holds ₹9.38 crore in fixed deposits from the previous preferential allotment pending utilization for capital expenditure and projects.

💡 Investors should exercise caution as the company has swung from a profit to a loss on a YoY basis and failed to convert 50% of its issued warrants. Monitor the progress of the Jammu and Kashmir project and the utilization of the remaining ₹9.38 crore cash for signs of operational turnaround.

JHS Svendgaard Grants 2.50 Lakh Stock Options Under ESOP Scheme 2025

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 10 Feb 2026, 02:43 PM

JHS Svendgaard Laboratories Limited has approved the grant of 2,50,000 Employee Stock Options (ESOPs) to eligible employees under its 2025 Scheme. Each option is convertible into one equity share of face value Rs. 10, with the exercise price also set at Rs. 10 per share. The vesting period begins one year from the grant date and extends up to five years, followed by a five-year exercise window. This initiative is designed to align employee interests with long-term shareholder value and improve retention.

Grant of 2,50,000 options convertible into an equal number of equity shares of Rs. 10 face value
Exercise price fixed at Rs. 10 per option, representing the face value of the shares
Vesting period ranges from a minimum of 1 year to a maximum of 5 years from the grant date
Exercise period allows employees to convert options within 5 years from the date of vesting
Scheme implemented through a direct route involving fresh allotment of shares by the company

💡 Investors should note the potential for minor equity dilution as these options are exercised over the coming years. No immediate action is required as this is a routine management practice to incentivize employees.

JHS Svendgaard Grants 2.5 Lakh ESOPs at Exercise Price of Rs 10

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 10 Feb 2026, 02:32 PM

JHS Svendgaard Laboratories Limited has announced the grant of 2,50,000 Employee Stock Options (ESOPs) under its 2025 Scheme. Each option is convertible into one equity share of face value Rs 10, with the exercise price also set at Rs 10 per share. The vesting period for these options ranges from one to five years from the date of grant. This move is aimed at employee retention and aligning staff interests with company performance.

Grant of 2,50,000 stock options to eligible employees under the ESOP Scheme 2025
Exercise price fixed at Rs 10 per share, which is the face value of the equity
Vesting period starts 1 year from the grant date and extends up to 5 years
Maximum exercise period of 5 years from the date of respective vesting
Implementation through direct route involving fresh allotment of equity shares

💡 This is a routine corporate action for employee retention with minimal immediate impact on share price. Investors should note the potential minor equity dilution that will occur over the next 1-5 years as options are exercised.

JHS Svendgaard Allots 18.01 Lakh Shares to Coeus Global Fund via Warrant Conversion

🟢 POSITIVE ⭐ 6/10

FUNDRAISE 📅 01 Feb 2026, 10:44 AM

JHS Svendgaard Laboratories has approved the allotment of 18,01,801 equity shares following the conversion of warrants by Coeus Global Opportunities Fund. The shares were issued at a price of Rs. 27.75 per share, resulting in the company receiving the final 75% payment amounting to approximately Rs. 3.75 crore. This conversion increases the company's total paid-up equity capital to Rs. 87.41 crore. Post-allotment, Coeus Global Opportunities Fund holds a 2.06% stake in the company.

Allotment of 18,01,801 equity shares at an issue price of Rs. 27.75 per share
Receipt of Rs. 3.75 crore representing the final 75% balance payment for warrant conversion
Total paid-up equity capital increased to Rs. 87.41 crore across 8.74 crore shares
Coeus Global Opportunities Fund now holds a 2.06% equity stake in the company

💡 The conversion indicates institutional interest and provides a capital boost to the company; investors should monitor the deployment of these funds for future growth.

JHS Svendgaard Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Jan 2026, 12:30 PM

JHS Svendgaard Laboratories has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Alankit Assignments Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that physical share certificates received were mutilated, cancelled, and the depository's name was updated in the records. This is a standard procedural filing required for all listed companies in India to maintain shareholding integrity.

Compliance certificate submitted for the quarter ending December 31, 2025.
Registrar Alankit Assignments Limited confirmed the processing of dematerialization requests.
Physical share certificates were verified, mutilated, and cancelled as per SEBI norms.
The name of the depository has been substituted in the records as the registered owner.

💡 No action is required as this is a routine administrative filing. Investors should continue to monitor the company's financial performance and operational updates.

JHS Svendgaard to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 05:42 PM

JHS Svendgaard Laboratories Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the declaration of financial results for the quarter and nine months ending December 31, 2025. The restriction applies to all designated persons and their immediate relatives. The trading window will remain closed until 48 hours after the financial results are officially announced to the exchanges.

Trading window closure begins on January 1, 2026
Closure pertains to financial results for the quarter and nine months ended December 31, 2025
Applies to all insiders, designated persons, and their immediate relatives
Window will reopen 48 hours after the board meeting results are declared

💡 This is a routine regulatory filing with no impact on business fundamentals. Investors should wait for the announcement of the board meeting date to assess the upcoming quarterly performance.

View All JHS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment, Oral Care. FY24 revenue declined 17% YoY due to a strategic realignment of the sales mix. However, Q4 FY24 revenue reached INR 21.66 Cr, representing a 51% increase over Q3 FY24 (INR 14.30 Cr) as new business in the toothbrush segment gained traction.

Geographic Revenue Split

For FY24, Domestic sales contributed 98.65% and Exports contributed 1.35%. In Q4 FY24, the split shifted slightly to 95.60% Domestic and 4.40% Export as international tie-ups began to regain space.

Profitability Margins

Gross margins improved as the company focused on better-margin products. PAT for Q4 FY24 was a loss of INR 0.75 Cr, which is a 92.98% improvement from the loss of INR 10.71 Cr in Q4 FY23. The company is targeting mid-teen EBITDA margins for FY25 through operational leverage.

EBITDA Margin

EBITDA margin for Q4 FY24 was 3.86%, a significant improvement of 2,023 bps compared to -16.37% in Q4 FY23. This was driven by a change in sales mix and a reduction in raw material and employee expenses.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company is focused on ramping up capacity utilization from the current 30% to 70% to drive growth without immediate heavy greenfield capex.

Credit Rating & Borrowing

Not disclosed in available documents. Interest and finance costs for Q4 FY24 were INR 0.13 Cr, up from INR 0.11 Cr YoY.

⚙️ Operational Drivers

Raw Materials

Key raw materials include formulations for Toothpaste, Mouthwash, Shampoo, Hand wash, and components for Toothbrushes (plastics/bristles).

Key Suppliers

Not disclosed in available documents; however, the company mentioned reworking costs from suppliers to improve the bottom line.

Capacity Expansion

Current capacity utilization is approximately 30%. The company plans to expand utilization to 70% by executing an order book of INR 110 Cr for FY25.

Raw Material Costs

Total Raw Material Expenses for Q4 FY24 were INR 14.65 Cr, representing 67.6% of revenue. This was a 4.60% decrease from INR 15.36 Cr in Q4 FY23, reflecting lower raw material prices and a better product mix.

Manufacturing Efficiency

Efficiency is being driven by improved manpower utilization and the addition of senior team members to oversee capacity utilization and deliveries.

📈 Strategic Growth

Expected Growth Rate

30-40%

Growth Strategy

Growth will be achieved through a 30-40% increase in sales via new client additions like Reliance (Retail and General Trade) and Amway, focusing on the export market, and pursuing substantial organic and inorganic acquisitions using current cash reserves and stock.

Products & Services

Toothbrushes (58.97% of FY24 revenue), Toothpaste (29.82%), Talcum Powder (7.92%), Mouthwash (3.29%), and other personal hygiene products like Shampoo and Hand wash.

Brand Portfolio

JHS Svendgaard. The company primarily acts as a private label and contract manufacturer for brands like Reliance, Amway, Zydus, and others.

New Products/Services

Expansion into Mouthwash and Talcum Powder segments, which contributed 3.29% and 7.92% to FY24 revenue respectively.

Market Expansion

Targeting the General Trade (GT) division of Reliance and increasing the export business, which started regaining space in Q4 FY24.

Strategic Alliances

Key partnerships include Reliance, Amway, and Zydus for domestic and retail supply.

🌍 External Factors

Industry Trends

The Indian contract manufacturing market is estimated to grow from USD 19.63 billion in 2023 to USD 38.92 billion by 2028, positioning JHS to benefit from the 'Make in India' push in FMCG.

Competitive Landscape

Competes with other large-scale contract manufacturers in the oral care and personal hygiene space.

Competitive Moat

The moat is built on established reputations with prominent FMCG brands and a diversified product portfolio in the oral care niche, which is sustainable as long as manufacturing standards remain high.

Macro Economic Sensitivity

Sensitive to FMCG consumption trends and raw material price fluctuations.

Consumer Behavior

Increasing focus on personal and home hygiene care products is driving demand for the company's expanded product lines.

Geopolitical Risks

Expansion into export markets increases exposure to international trade barriers and geopolitical stability.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, and Ind AS 108 for segment reporting.